Baylor Health Care SystemAbout B
Research: From moving better to recovering faster, here's what we're studying. 
Need something? Call us: 1.800.4BAYLOR(1.800.422.9567)
Text Size:

  


A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer




A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients (USON MK8669-064)

Study Description:

The purpose of the study is to evaluate the progression free survival (PFS) of ridaforolimus, dalotuzumab and exemestane (R/D/E) compared to the combination of ridaforolimus and exemestane (R/E) in post-menopausal participants with breast cancer.

Inclusion Criteria:

» Females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive, Human Epidermal Growth Factor Receptor 2 (HER-2) negative, Ki67 (a tumor marker) ≥ 15%
» Post-menopausal
» With advanced breast cancer whose disease was refractory to previous letrozole or anastrozole
» Has at least one confirmed measurable metastatic lesion
» Has a performance status ≤ 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale
» Has a life expectancy of at least 3 months
» Adequate organ function

Exclusion Criteria:

» Is receiving any other concurrent systemic tumor therapy, including hormonal agents and HER-2 inhibitors
» Previously received rapamycin or rapamycin analogs, including ridaforolimus, temsirolimus, or everolimus
» Received prior treatment with Insulin-like Growth Factor 1 Receptor (IGF-1R) inhibitors, Phosphatidylinositol 3-Kinase (PI3K) inhibitors, or other experimental agents that target PI3K, Protein Kinase B (AKT), or Mammalian Target of Rapamycin (mTOR) pathway
» Is receiving chronic corticosteroids administered at doses greater than those used for normal replacement therapy
» Has active brain metastasis or leptomeningeal carcinomatosis; patients with adequately treated brain metastases are eligible if they meet certain criteria
» Known allergy to macrolide antibiotics
» Has an active infection requiring antibiotics
» Significant or uncontrolled cardiovascular disease
» Poorly controlled Type 1 or 2 diabetes
» Is known to be Human Immunodeficiency Virus (HIV) positive
» Has a known history of active Hepatitis B or C

Locations:


Texas Oncology - Baylor Charles A. Sammons Cancer Center
3410 Worth Street
Dallas , TX 75246

Texas Oncology - Baylor Regional Medical Center at Grapevine
1650 West College
Grapevine , TX 76051

Lead Principal Investigator:

Thomas C. Anderson, MD (Grapevine); Joanne Blum, MD (Dallas)



This trial is no longer available for enrollment.

Last update: December 28, 2012
† Baylor Research Institute and Texas Oncology are not affiliated. Each reviews, approves, and conducts clinical trials independently. Their clinical trials are listed together on this website for the convenience of patients.